![]() Rates of new disease are at a new low in the UK according to the ZOE app, due to a combination of social measures and vaccination and we need to continue this successful strategy to cover the remaining population”. Professor Tim Spector OBE, lead scientist on the ZOE COVID Symptom Study app and Professor of Genetic Epidemiology at King’s said: “The data should reassure many people that in the real world, after effects of the vaccine are usually mild and short-lived, especially in the over 50’s who are most at risk of the infection. While rates of side effects were much lower than expected from clinical trials, rates of infection after vaccine were reassuring after two- three weeks and in line with findings from previous trials and recent data from the Israeli vaccination programme. Similarly, in Phase III trials for the AstraZeneca vaccine, systemic side effects were found in 88% of younger participants (18-55 years) after the first dose but this study found a significantly lower rate of 46.2% after the first dose. In Phase III clinical trials of the Pfizer vaccine, the most common side effects were pain at the injection site (71-83%), fatigue (34-47%) and headache (25-42%), however the real-world analysis found less than 30% of users complained of injection site pain and less than 10% of fatigue and headache after the first dose. People with prior known COVID-19 infection were also more likely to experience local effects. Importantly, this research identifies that side effects were more common among people under 55 years of age and among women.Īlso, participants who had a confirmed case of prior COVID-19 were three times more likely to have side effects that effect the whole body after receiving doses of the Pfizer vaccine than those without known infection and almost twice more likely after the first dose of the AstraZeneca vaccine.
0 Comments
Leave a Reply. |